TEMENOS
3.11.2020 10:02:06 CET | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced that registration is open for Temenos SCALE on the 17-18 November 2020. Temenos SCALE is the biggest developer conference in the banking industry, attracting developers from over 106 countries and from every type and size of institution across the banking industry. At Temenos SCALE, this global developer community will experience hands-on workshops, presentations and demonstrations with a focus on Explainable AI, microservices and open APIs and cloud technologies. Register here for this free to attend event.
Paul Roberts, Director, Temenos Developer Community & MarketPlace, Temenos, said: “Developers love Temenos because we have the most advanced technology, the richest ecosystem and the largest customer base of the most ambitious and challenger banks. We recognize the vital role our developer community plays in shaping the future of banking and we are committed to developers’ success. We invest an industry leading 20 per cent of our revenues into research and development – a further $1bn investment over just the next few years. And we are making significant investment in our developers too, supporting them with the tools, skills and knowledge to use our technology to solve real world problems at scale. Our API-first technology and modern microservices-based architecture enables rapid innovation and our MarketPlace gives developers a shop window into banks serving more than one billion people around the world. Banking truly is the most exciting space for developers right now and Temenos SCALE is the flagship event to bring the developer community together, to learn, share and grow.”
Attendees of Temenos SCALE will hear from influential technology and banking industry leaders. Temenos CEO Max Chuard will keynote on why now is a pivotal moment in the banking industry, how developers are shaping the future and making banking a force for good and how Temenos is supporting them with innovative technologies to create and bring new products to market faster.
Banks face mounting pressure as they try to keep pace with evolving customer expectations, competition and changing regulations. Covid-19 has accelerated the shift to digital banking and SaaS; Open Banking regulation is splitting the value chain and proving a catalyst for innovation; and with the rise of big tech, customers now expect seamless, hyper-personalized experiences. These trends are driven and enabled by technology and banks increasingly need developers to help them survive and thrive in this digital-first era.
The Temenos SCALE event will include over 40 sessions, including hands-on workshops and product demonstrations. Attendees will also hear from Temenos’ technology partners and customers. ABN AMRO will share insights on the power of analytics, Openbank on the extensibility of Temenos Transact to differentiate and Canadian Western Bank on design thinking. The event is supported by IBM as the headline sponsor, Microsoft, Red Hat, TailWind, NuoDB and Syncordis,
Andre Tost, Distinguished Engineer and CTO, IBM Cloud Pak Architecture, said: “At Temenos SCALE, you’ll hear about how IBM and our business partner Temenos are working together to bring hybrid cloud solutions to banking, and deliver greater automation, innovation and integration capabilities to our joint clients. I hope you’ll join us as we explore the incredible advances of modern software and API-led technology built with IBM offerings, like LinuxONE and IBM Cloud Paks. We look forward to engaging the brightest minds in the developer community – today’s change leaders – to discuss how we can work together to create powerful change in the banking industry on a global scale.”
Follow #TemenosSCALE on social media for live updates on LinkedIn, Twitter, Facebook and Instagram.
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201103005032/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom